
For most marketing authorisation holders, the question of when a periodic safety update report is due is not answered by the marketing authorisation itself. It[…]

Since 5 February 2026, patients in Greece receiving certain high-cost medicines have been able to collect them from a private community pharmacy of their choice,[…]

Since the White House’s May 2025 executive order on most-favoured-nation (MFN) pricing, US drug prices have become increasingly linked to prices paid in other high-income[…]

More than a year after the consultation closed, the revised EU GMP Annex 11 on computerised systems and the new Annex 22 on artificial intelligence[…]

Cloud and software-as-a-service platforms now run quality management, pharmacovigilance, regulatory information and laboratory processes across the industry. They also change on the vendor’s schedule, often[…]

In October 2026, the US Food and Drug Administration finalised its guidance on Prescription Drug Use-Related Software (PDURS), three years after the 2023 draft. It[…]

Modelling and simulation now support dose selection, paediatric extrapolation, drug interaction claims and trial design across most development programmes. ICH M15, adopted at Step 4[…]

Extractables and leachables have long been assessed through a patchwork of regional guidance, pharmacopoeial chapters and industry practice. ICH Q3E is set to become the[…]

ICH finalised Annex 2 to the E6(R3) Good Clinical Practice guideline on 3 June 2026. Where the core E6(R3) principles and Annex 1 describe GCP[…]

On 16 October 2026, the US Food and Drug Administration announced that CDER and CBER will accept eCTD v4.0 submissions to applications that were originally[…]